ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Dna methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells

Candelaria M; de la Cruz Hernandez E; Taja Chayeb L; Perez Cardenas E; Trejo Becerril C; Gonzalez Fierro A; Chavez Blanco A; Soto Reyes E; Dominguez G; Trujillo J E; Diaz Chavez J; Duenas Gonzalez A*
PLoS ONE2012DOI: 10.1371/journal.pone.0029181
12阅读
引用收藏
分享

摘要

Background: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent. Hydralazine has been shown to reverse doxorubicin resistance in a model of breast cancer. Here we wanted to investigate whether epigenetic mechanisms are responsible for acquiring resistance to gemcitabine and if hydralazine could restore gemcitabine sensitivity in cervical cancer cells. Methodology/Principal Findings: The cervical cancer cell line CaLo cell line was cultured in the presence of increasing concentrations of gemcitabine. Down-regulation of hENT1 & dCK genes was observed in the resistant cells (CaLoGR) which was not associated with promoter methylation. Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. No changes in HDAC total activity nor in H3 and H4 acetylation at these promoters were observed. ChIP analysis showed H3K9m2 at hENT1 and dCK gene promoters which correlated with hyper-expression of G9A histone methyltransferase at RNA and protein level in the resistant cells. Hydralazine inhibited G9A methyltransferase activity in vitro and depletion of the G9A gene by iRNA restored gemcitabine sensitivity. Conclusions/Significance: Our results demonstrate that acquired gemcitabine resistance is associated with DNA promoter methylation-independent hENT1 and dCK gene down-regulation and hyper-expression of G9A methyltransferase. Hydralazine reverts gemcitabine resistance in cervical cancer cells via inhibition of G9A histone methyltransferase.

被引文献 (1)相关
加载中…
  • Pharmacoepigenomics and Pharmacovigilance in Gynecological Cancers
    Ang, SunGynecological Cancers, Springer International Publishing, 23-47, 2016.

发表信息

论文状态
公开发表
期刊
PLoS ONE
发表日期
2012
卷期
第 7 卷, 第 3 期
DOI
10.1371/journal.pone.0029181
语言
ENGLISH
成果收录
SCOPUS

作者

  • C

    Candelaria M (第一作者)

  • d

    de la Cruz Hernandez E

查看全部 12 位作者收起作者
  • T

    Taja Chayeb L

  • P

    Perez Cardenas E

  • T

    Trejo Becerril C

  • G

    Gonzalez Fierro A

  • C

    Chavez Blanco A

  • S

    Soto Reyes E

  • D

    Dominguez G

  • T

    Trujillo J E

  • D

    Diaz Chavez J

  • D

    Duenas Gonzalez A (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417